Evidence versus practice involving universal acceptance of neoadjuvant chemotherapy in muscle-invasive bladder cancer: Results from a tertiary care center in India
Indian Journal of Cancer · 2025
DOI: 10.4103/ijc.ijc_1529_21 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Cancer, 2025. Verfasst von Shivcharan Navriya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Neoadjuvant Therapy. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
We reviewed the pattern of neoadjuvant chemotherapy (NACT) utilization at our center for patients with muscle-invasive bladder cancer (MIBC) to analyze the reasons behind the delay in cystectomy.
Methods
A retrospective study was planned to review all the cases of carcinoma bladder cT2-T4, N0-3, and M0 with muscle invasion, planned for NACT followed by radical cystectomy (RC) from September 2019 to March 2021. The aim of the study was to identify the barriers and factors that cause a delay in the initiation and continuation of neoadjuvant chemotherapy as well as a delay in radical cystectomy masking the proposed survival advantage of neoadjuvant chemotherapy.
Results
A total of 41 patients with MIBC were planned for NACT. The mean age was 53.75 years (range: 24–68 years). The average time from diagnosis to Transurethral resection of bladder tumor (TURBT), from TURBT to initiation of NACT, for completion of NACT, and from completion to NACT to RC were 17.25, 45.28, 73.15, and 20.12 days, respectively. Out of the 41 patients, 32 (78.1%) received at least the first cycle of NACT, 19 (46.3%) completed NACT, and eight (19.5%) underwent RC. Reasons for delay were attributed to poor compliance, financial reasons, adverse events, subjective feeling of well-being, and COVID-19-associated lockdown.
Conclusion
Several patient-related, treatment-related, and disease-related factors have been identified that result in the underutilization of NAC and unnecessary delay in radical cystectomy. In view of a logistical delay due to these factors, NAC can be avoided in those patients who are expected to have poor compliance, who come from remote areas, or have poor access to health care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
- Department of Medical Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
ORCID-Profile: Harkirat Singh Talwar
Zitieren
APA
Navriya, S., Talwar, H. S., Mittal, A., Kumar, S., Panwar, V. K., Sehrawat, A., & Mandal, A. K. (2025). Evidence versus practice involving universal acceptance of neoadjuvant chemotherapy in muscle-invasive bladder cancer: Results from a tertiary care center in India. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_1529_21
Vancouver
Navriya S, Talwar HS, Mittal A, Kumar S, Panwar VK, Sehrawat A, et al. Evidence versus practice involving universal acceptance of neoadjuvant chemotherapy in muscle-invasive bladder cancer: Results from a tertiary care center in India. Indian Journal of Cancer. 2025. doi:10.4103/ijc.ijc_1529_21
BibTeX
@article{Navriya2025,
author = {Navriya, Shivcharan and Talwar, Harkirat Singh and Mittal, Ankur and Kumar, Sunil and Panwar, Vikas Kumar and Sehrawat, Amit and Mandal, Arup Kumar},
title = {Evidence versus practice involving universal acceptance of neoadjuvant chemotherapy in muscle-invasive bladder cancer: Results from a tertiary care center in India},
journal = {Indian Journal of Cancer},
year = {2025},
doi = {10.4103/ijc.ijc_1529_21}
}
EUVIMED